Results 31 to 40 of about 34,041 (183)
BMC Cancer, 2022 Objective Whether preoperative serum carbohydrate antigen 19–9 (CA19-9) is an independent prognostic factor and there are interactions of serum CA19-9 with carcinoembryonic antigen (CEA) on the risk of recurrence in colorectal cancer (CRC) patients are ...
Zhenhui Li +15 more
doaj +1 more source
CA19-9 for detecting recurrence of pancreatic cancer [PDF]
Scientific Reports, 2020 AbstractCA19-9 values are regularly measured in patients with pancreatic cancer. Certainly, its potential as a biomarker has been compromised by false negative results in CA19-9 negative patients and false positive results in benign pancreatico-biliary diseases. For detection of PDAC recurrence, however, CA19-9 might play an important role.
Azadeh Azizian +9 more
openaire +3 more sources
Discover Oncology, 2023 Background Carbohydrate antigen 19–9 (CA19-9) is the most widely used biomarker for pancreatic cancer. Since CA19-9 closely correlates with patient outcome and tumor stage in pancreatic cancer, the deciphering of CA19-9 biosynthesis provides a potential ...
Chen Liu +10 more
doaj +1 more source
Urinary CE-MS peptide marker pattern for detection of solid tumors [PDF]
, 2018 Urinary profiling datasets, previously acquired by capillary electrophoresis coupled to mass-spectrometry were investigated to identify a general urinary marker pattern for detection of solid tumors by targeting common systemic events associated with ...
Belczacka, Iwona +8 more
core +2 more sources
Journal of Diabetes Investigation, 2020 Aims/Introduction Elevated serum cancer antigen 19‐9 (CA19‐9) levels have been found in diabetes patients in most observational studies; however, whether there is a causal association between CA19‐9 and diabetes mellitus is unclear. Materials and Methods
Zhaoyang Li +12 more
doaj +1 more source
Scientific Reports, 2021 Despite the acceptance of carbohydrate antigen 19-9 (CA19-9) as a valuable predictor for the prognosis of pancreatic ductal adenocarcinoma (PDAC), its cutoff value remains controversial.
Fumiaki Watanabe +12 more
doaj +1 more source
Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]
, 2001 Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core +1 more source
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]
, 2002 Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Heinemann, Volker +2 more
core +1 more source
CA19-9 elevation in ovarian mature cystic teratoma: Discrimination from ovarian cancer – CA19-9 level in teratoma [PDF]
Medical Science Monitor, 2013 We aimed to identify clinical characteristics of ovarian mature cystic teratoma (MCT) in association with CA19-9 elevation, and to determine if CA19-9 is a useful marker in discrimination of MCT from ovarian cancer (OC).Medical records of 322 women with pathologically-confirmed MCT or OC (stage 1 or 2) were reviewed retrospectively.
Cho, Hye-yon +4 more
openaire +2 more sources
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]
, 2007 Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Boeck, Stefan +9 more
core +1 more source